Published in Proc Natl Acad Sci U S A on January 19, 2004
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
Impaired FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A (2007) 2.94
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 1.90
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 1.82
An essential role for FGF receptor signaling in lens development. Semin Cell Dev Biol (2006) 1.58
The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization. Sci Signal (2010) 1.22
A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Adv Urol (2012) 1.16
Microfluidic perfusion for regulating diffusible signaling in stem cells. PLoS One (2011) 1.14
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol (2005) 1.13
Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice. BMC Dev Biol (2010) 1.11
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 1.10
Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes. Biochemistry (2009) 1.09
Physical-chemical principles underlying RTK activation, and their implications for human disease. Biochim Biophys Acta (2011) 1.06
Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland. Orphanet J Rare Dis (2011) 1.04
Hand in glove: brain and skull in development and dysmorphogenesis. Acta Neuropathol (2013) 1.04
Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1. J Biol Chem (2009) 1.01
Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. J Chem Inf Model (2008) 1.01
Conditionally and transiently disordered proteins: awakening cryptic disorder to regulate protein function. Chem Rev (2014) 1.00
Multimers of the fibroblast growth factor (FGF)-FGF receptor-saccharide complex are formed on long oligomers of heparin. Biochem J (2006) 1.00
Physical basis behind achondroplasia, the most common form of human dwarfism. J Biol Chem (2010) 0.99
Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol (2012) 0.96
NMR structure of the first Ig module of mouse FGFR1. Protein Sci (2006) 0.94
Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol Cell Biol (2009) 0.94
Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies. Nat Commun (2013) 0.93
Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog (2013) 0.91
The physical basis of FGFR3 response to fgf1 and fgf2. Biochemistry (2011) 0.91
p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice. J Clin Invest (2012) 0.90
Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1. Protein Sci (2006) 0.89
Poly(ethylene glycol)-based biosensor chip to study heparin-protein interactions. Anal Biochem (2005) 0.86
Mechanism of FGF receptor dimerization and activation. Nat Commun (2016) 0.86
The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure (2012) 0.85
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors (Basel) (2009) 0.83
Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. J Biol Chem (2011) 0.83
A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. BMC Bioinformatics (2014) 0.83
Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor. Oncotarget (2016) 0.82
A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer (2014) 0.82
The evolutionary fate of alternatively spliced homologous exons after gene duplication. Genome Biol Evol (2015) 0.81
Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3. PLoS One (2013) 0.81
Structural basis for the activation of FGFR by NCAM. Protein Sci (2008) 0.81
Genetic variation at hair length candidate genes in elephants and the extinct woolly mammoth. BMC Evol Biol (2009) 0.81
Specificity in molecular design: a physical framework for probing the determinants of binding specificity and promiscuity in a biological environment. J Phys Chem B (2007) 0.81
The structural biology of the FGF19 subfamily. Adv Exp Med Biol (2012) 0.81
Influence of heparin mimetics on assembly of the FGF.FGFR4 signaling complex. J Biol Chem (2010) 0.81
Conserved intron positions in FGFR genes reflect the modular structure of FGFR and reveal stepwise addition of domains to an already complex ancestral FGFR. Dev Genes Evol (2009) 0.80
Nectin-1 binds and signals through the fibroblast growth factor receptor. J Biol Chem (2012) 0.79
Cubilin, a high affinity receptor for fibroblast growth factor 8, is required for cell survival in the developing vertebrate head. J Biol Chem (2013) 0.79
Unliganded Fibroblast Growth Factor Receptor 1 Forms Density-independent Dimers. J Biol Chem (2015) 0.78
Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol Med (2016) 0.75
Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors. Biomed Res Int (2016) 0.75
Weak conservation of structural features in the interfaces of homologous transient protein-protein complexes. Protein Sci (2015) 0.75
Targeting FGFR in Squamous Cell Carcinoma of the Lung. Target Oncol (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell (1991) 8.99
Receptor specificity of the fibroblast growth factor family. J Biol Chem (1996) 7.58
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell (2000) 5.72
Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res (1993) 4.67
Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A (1992) 4.50
Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol (1992) 3.41
Structural basis for FGF receptor dimerization and activation. Cell (1999) 3.19
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell (2000) 2.99
The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol (1998) 2.36
Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J (1992) 2.00
Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci U S A (1991) 1.94
A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J (1992) 1.93
Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci U S A (2000) 1.76
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.62
Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry (1994) 1.53
A novel form of fibroblast growth factor receptor 2. Alternative splicing of the third immunoglobulin-like domain confers ligand binding specificity. J Biol Chem (1992) 1.52
Alternately spliced NH2-terminal immunoglobulin-like Loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem (1995) 1.21
Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J Biol Chem (1999) 1.14
Expression and immunochemical analysis of rat and human fibroblast growth factor receptor (flg) isoforms. J Biol Chem (1992) 1.02
A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem (2000) 1.00
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 9.62
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev (2005) 4.69
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 4.00
FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A (2009) 3.99
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature (2010) 3.52
Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev (2005) 3.28
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest (2007) 3.20
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Impaired FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A (2007) 2.94
Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell (2007) 2.83
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest (2007) 2.79
Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab (2008) 2.76
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest (2008) 2.69
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A (2012) 2.38
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol (2005) 2.35
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep (2006) 2.29
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell (2006) 2.21
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J (2008) 2.03
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Flexible energy storage devices based on nanocomposite paper. Proc Natl Acad Sci U S A (2007) 2.02
Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol (2005) 2.00
Current status of surgery in dermatology. J Am Acad Dermatol (2013) 1.98
Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice. J Cell Biol (2007) 1.92
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 1.90
The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc Natl Acad Sci U S A (2004) 1.89
Electron detachment dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2006) 1.89
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2006) 1.87
A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A (2002) 1.86
Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem (2003) 1.86
Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (2004) 1.84
Mutations in different components of FGF signaling in LADD syndrome. Nat Genet (2006) 1.76
Retracted A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control. EMBO J (2005) 1.72
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol (2004) 1.71
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol (2009) 1.70
The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell (2009) 1.68
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell (2004) 1.64
Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem (2010) 1.64
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.62
Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol (2006) 1.62
A structure-based model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci U S A (2004) 1.62
Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation. Anal Chem (2007) 1.61